Sunmax
Develops high-standard collagen-based medical devices and bioprinting materials for tissue regeneration.
- CEO / Founder
- Lin Chi-Hsien
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $17M
- Latest Round
- IPO
- Key Investors
- Publicly traded (TPEx: 4728); Institutional investors in Taiwan
Technology & Products
Key Products
Porcogen
Technological Advantage
Enables the creation of 3D printed scaffolds for tissue engineering using liquid collagen inks that maintain biological integrity during the printing process.
Differentiation
Value Proposition
Provides pig-based collagen (Porcogen) that remains liquid pre-fibrillized, enabling high-precision 3D printing of scaffolds for artificial tissues and cell culture with improved biological integrity.
How They Differentiate
Proprietary SPF (Specific Pathogen Free) porcine collagen extraction achieves 99.9% purity, offering higher thermal stability and lower immunogenicity compared to traditional bovine-derived collagen or tobacco-based rhCollagen (CollPlant).
Market & Competition
Target Customers
Aesthetic medicine clinics, orthopedic surgeons, and regenerative medicine researchers requiring medical-grade collagen bio-inks for tissue engineering.
Industry Verticals
Medical; Biotechnology
Competitors
CollPlant Biotechnologies; Advanced BioMatrix; Rousselot
Growth & Milestones
Growth Metrics
Sales grew to TWD 1,752.89 million in 2025 from 1,262.82 million in the prior year; net income reached TWD 209.78 million (data for related Sun Max Tech entity).
Major Milestones
Founded in 2001; Publicly listed in Taiwan since at least 2017; Developed Porcogen pig-based collagen for bioprinting
Notable Customers
National Taiwan University Hospital; Taipei Veterans General Hospital; Various Tier-1 aesthetic clinics in Mainland China and Taiwan